TLDR Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
The document discussed the use of JAK inhibitors (JAKi) like tofacitinib for treating alopecia areata (AA) during the COVID-19 pandemic. It highlighted concerns about increased infection risks due to JAKi, given their role in the JAK/STAT pathway, which is involved in severe COVID-19 cases. The study reported on three AA patients in Hubei, China, who took JAKi during the pandemic and did not contract COVID-19. Two patients showed hair growth, while one did not. The authors concluded that JAKi did not increase COVID-19 infection risk in these cases but emphasized the need for more data to confirm the safety and efficacy of JAKi during the pandemic. They also provided recommendations for safely continuing clinical trials during such times.
54 citations,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
40 citations,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
63 citations,
April 2018 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help treat some skin conditions but need more research.
53 citations,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
4 citations,
June 2023 in “Frontiers in immunology” JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.